NordicCan, a full Contract Development and Manufacturing Organisation specialized in innovative cannabinoid solutions for the B2B market, announced that the Canadian Intellectual Property Office has issued patent numbers CA 3,031,530 and CA 3,035,400 covering the use of cannabinoids within NordicCan’s extruded and compressed chewing gum formulations, including its unique bi-layered compressed gum format.
“These patents represent a key milestone in securing NordicCan’s competitive position in the market of cannabinoids for wellness and medical purposes with products that are convenient, and have a pleasurable mouthfeel through unique taste and texture,” said Julie Malbaek, CEO, NordicCan. “The market for wellness & medical use is expected to grow substantially in the coming years. With our comprehensive patent portfolio, NordicCan is well positioned to support the industry with suitable and flexible delivery formats across retail channels and application areas”, she added.
For more information about this announcement, visit www.nordiccan.com
Julie Malbaek, CEO – NordicCan A/S, JULM@fertin.com
Jesper Neergaard, Senior Principal, Head of IPR at Fertin Pharma and NordicCan, JNR@fertin.com
About NordicCan A/S:
NordicCan A/S, a sister company of Fertin Pharma, develops and produces innovative cannabinoid containing products based on unique oral and intra-oral delivery systems. With a health focus, NordicCan defines its business scope within Wellness, Medicinal and Pharmaceutical approved cannabinoid containing formats. Fertin Pharma and NordicCan jointly have access to and mastery of the most comprehensive portfolio of intra-oral delivery systems globally. They own a wide range of patents covering several oral and intra-oral delivery technologies, which offer the patient and consumer efficient, pleasurable and convenient delivery formats.